Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. An experimental gene therapy from Uniqure slowed the progression of …
Read More »Uniqure gene therapy for Huntington’s slowed disease progression in key trial
